

- Shortness of breath when lying flat
- Blisters
- Low blood pressure.

Not known: Frequency cannot be estimated from the available data

- Anaphylactic reaction (serious allergic reaction which causes difficulty in breathing or dizziness, swelling of the face or throat)
- Changes in ECG (QT prolongation)
- General discomfort
- Anxiety
- Rapid formation of wheals due to swelling of the skin or mucous membranes
- Urinary incontinence
- If an existing pituitary tumour, an increased risk of bleeding to the area.
- Anaemia (decrease in the count of red blood cells).

In children:

Side effects which are **very common** (may affect more than 1 in 10 people) are:

- Vaginal bleeding which may occur in girls in the first month of treatment.

Side effects which are **common** (may affect up to 1 in 10 people) are:

- Acne
- Headache
- Hot flushes
- Weight gain
- Pain in the abdomen
- Hypersensitivity reactions
- Pain, redness and swelling at injection site.

Side effects that are **uncommon** (may affect up to 1 in 100 people) are:

- Itching
- Neck pain
- Nosebleeds
- Constipation
- Blurred vision
- Rash or hives
- Nausea, vomiting
- Overweight
- Pain in the breast
- Changes in mood
- General discomfort.

Not known: Frequency cannot be estimated from the available data

- High blood pressure
- Abnormal vision
- Severe allergic reaction which causes difficulty swallowing, breathing problems, swelling of your lips, face, throat or tongue, or hives
- Convulsions
- Some blood tests affected including hormone levels
- Rapid formation of wheals due to swelling of the skin or mucous membranes
- Muscle pain
- Mood disorders
- Depression
- Nervousness.
- Idiopathic intracranial hypertension (increased intracranial pressure around the brain characterised by headache, double vision and other visual symptoms, and ringing or buzzing in the ears)

Your doctor will determine the countermeasures be to taken.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance: Website: www.hpra.ie; By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Decapeptyl 6-month

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the box and on the labels after EXP. The expiry date refers to the last day of that month.

Once opened/reconstituted, immediate use is recommended.

Do not store above 25°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Decapeptyl 6-month contains

The active substance of Decapeptyl 6-month is triptorelin. Each vial contains the quantity of triptorelin (as triptorelin pamoate) to ensure that the minimum triptorelin quantity injected is 22.5 mg.

For product imported from Belgium and Greece:

The other ingredients are poly (D,L-lactide-co-glycolide), mannitol, carmellose sodium, polysorbate 80. The solvent contains water for injections.

For product imported from Czech Republic:

the other ingredients are Polyglactin, mannitol, carmellose sodium, polysorbate 80. The solvent contains water for injections.

What Decapeptyl 6-month looks like and the contents of the pack

Decapeptyl 6-month is supplied as an off-white powder in a clear glass vial. Each vial contains enough product for one injection. The solvent contains 2mL of a clear, colourless liquid in a glass ampoule. Once reconstituted, around 2mL of milky liquid is formed.

After dispersion in 2mL solvent, 1mL of the reconstituted suspension contains 11.25mg triptorelin.

Decapeptyl 6-month is available in boxes of:

1 vial, 1 ampoule and 1 blister containing 1 injection syringe and 2 injection needles.

Parallel Product Authorisation Holder: IMED Healthcare Ltd, Unit 625 Kilshane Avenue, Northwest Business Park, Ballycoolin, Dublin 15, Ireland.

Manufacturer: IPSEN PHARMA BIOTECH, Parc d'Activités du Plateau de Signes, Chemin départemental 402, 83870 Signes, France.

Repackaged by: Cast Healthcare Ltd, Unit E, The Business Centre, 5-7 Tobermore Road, Draperstown, Magherafelt, BT45 7AG, UK(NI) or IMED Healthcare Ltd, Unit 625 Kilshane Avenue, Northwest Business Park, Ballycoolin, Dublin 15, Ireland






This leaflet was last revised in March 2025.

Product imported from Czech Republic is called ‘DIPHERELINE S.R. 22,5 mg prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním

Product imported from Greece is called ‘Arvekap 22,5 mg κόνις και διαλύτης για ενέσιμο εναιώρημα παρατεταμένης αποδέσμευσης’.

The following information is intended for medical or healthcare professionals only:

INSTRUCTIONS FOR RECONSTITUTION

1. PREPARATION OF THE PATIENT BEFORE RECONSTITUTION	
○ Prepare the patient by disinfecting the injection site. This operation needs to be performed first because once reconstituted, the drug should be injected immediately.	
2. PREPARATION OF THE INJECTION	
Two needles are provided in the box : ○ Needle 1 : a 20G needle (38 mm of length) without safety device to be used for reconstitution. ○ Needle 2 : a 20G needle (38 mm of length) with safety device to be used for injection. Needle 1 - 38 mm Needle 2 - 38 mm	
The presence of bubbles on top of the lyophilisate is a normal appearance of the product. The following steps must be completed in a continuous sequence.	
A 	2a ○ Take out the ampoule containing the solvent. Tap any solution within the tip of the ampoule back to the main body of the ampoule. ○ Screw Needle 1 (without safety device) on to the syringe. Do not remove the needle protection yet. ○ Break open the ampoule with dot face up. ○ Remove the needle protection from Needle 1. Insert the needle in the ampoule and draw up all the solvent into the syringe. ○ Put aside the syringe containing the solvent.
B 	2b ○ Take out the vial containing the powder. Tap any powder which has accumulated at the top of the vial back to the bottom of the vial. ○ Remove the plastic tab on top of the vial. ○ Take back the syringe containing the solvent and insert the needle through the rubber stopper vertically into the vial. Inject the solvent slowly, so that, if possible, it washes down the entire upper part of the vial.
C 	2c ○ Pull up Needle 1 above the liquid level. Do not remove the needle from the vial. Reconstitute the suspension, by swirling gently from side to side. Do not invert the vial. ○ Continue swirling long enough (at least 30 seconds) to obtain a homogenous and milky suspension. ○ Important: Check there is no unsuspended powder in the vial (if any powder clumps are present, continue swirling until they disappear).
D  E 	2d • When the suspension is homogenous, pull down the needle and without inverting the vial, draw up all of the suspension. A small amount will remain in the vial and should be discarded. An overfill is included to allow for this loss. • Grasp the coloured hub to disconnect the needle. Remove Needle 1 used for the reconstitution from the syringe. Screw on to the syringe Needle 2. • Move the safety sheath away from the needle and towards the syringe barrel. The safety sheath remains in the position you set. • Remove the needle protection from the needle. • Prime the needle to remove air from the syringe and inject immediately.
3. INTRAMUSCULAR INJECTION	
F 	• To avoid sedimentation, inject immediately into the disinfected area as quickly as possible (within 1 minute from reconstitution).
4. AFTER USE	
○ Activation of the safety system using a one-handed technique. ○ Note: Keep your finger behind the tab at all times.	
There are two alternatives to activate the safety system: ○ Method A: push the tab forward with your finger < 90° Tab  Method A	
Or	
○ Method B: push the sheath to a flat surface.  Method B	
○ In both cases press down with a firm quick motion until a distinct audible click is heard.	
○ Visually confirm that the needle is fully engaged under the lock. Lock 	
○ Used needles, any unused suspension or other waste materials should be disposed of in accordance with local requirements.	